The SCN1A gene codes the alpha subunit of the voltage-gated sodium ion channel. It is a member of ten paralogous gene families which code the voltage-gated sodium transmembrane proteins NaV1.1. The SCN1A gene is located on chromosome 2 of humans and consists of 26 exons spanning a total length of 6030 nucleotide base pairs (bp). The protein contains four internal repeat sequences, each of which has five hydrophobic segments (S1, S2, S3, S5, S6) and a positively charged segment (S4). Segment S4 may be a voltage sensor and has a series of positively charged amino acids at each third position.
|Basic Information of SCN1A|
|Protein Name||Sodium channel protein type 1 subunit alpha|
|Aliases||Sodium channel protein brain I subunit alpha, Sodium channel protein type I subunit alpha, Voltage-gated sodium channel subunit alpha Nav1.1|
|Organism||Homo sapiens (Human)|
SCN1A membrane protein mediates the voltage-dependent sodium ion permeability of excitable membranes. In response to a voltage difference across the membrane, the conformation is turned on or off to form a sodium-selective channel through which Na+ ions can pass according to the electrochemical gradient. SCN1A plays a key role in the brain, probably by regulating the moment when neurotransmitters are released in neurons. It involves the sensory perception of mechanical pain. Diseases associated with SCN1A include generalized epilepsy with febrile seizures plus 2 (GEFS+2), migraine, familial hemiplegic 3 (FHM3), early infantile epileptic encephalopathy-6 and intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC) and familial febrile seizures 3A (FEB3A). These diseases are caused by mutations affecting the gene represented in this entry.
This article finds that mutations in SCN1A and SCN2A are a predisposing factor of acute encephalopathy with biphasic seizures and late reduced diffusion. Altered channel activity caused by these mutations may provoke seizures and excitotoxic brain damage.
This article suggests a huge difference in electrophysiological function between SCN1A and SCN3A mutations in the pore region.
This article suggests FCD can influence the electroclinical pattern in patients with SCN1A mutations.
This article reveals that SCN1A gene polymorphisms are related to plasma levels of CBZ and CBZE.
This article suggests that in a clinically heterogeneous cohort, although biased toward DS phenotype, 46% of the patients have epilepsy caused by SCN1A mutations and the mutation ratio among DS patients are 41.3% which is significantly lower than the reported ratio.
Membrane protein studies have advanced significantly over the past few years. Based on our versatile Magic™ membrane protein production platform, we could offer a series of membrane protein preparation services for worldwide customers in reconstitution forms as well as multiple active formats. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SCN1A antibody development services.
During the past years, Creative Biolabs has successfully generated many functional membrane proteins for our global customers. We are happy to accelerate the development of our clients’ programs with our one-stop, custom-oriented service. For more detailed information, please feel free to contact us.
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.